![Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/Taxus_stent_FDA-e1607803635904-350x250.jpg)
Paclitaxel-coated devices do not reduce rates of major amputations in chronic limb-threatening ischemia
1. All-cause mortality and reduction in major amputations were similar between groups. 2. The rate of target vessel reintervention was ...
Tag: paclitaxel
Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma
1. Progression-free survival was significantly greater in retifanlimab compared to placebo. 2. Serious and grade 3 or more adverse events ...
Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients
1. Progression-free and overall survival were greater in relacorilant plus nab-paclitaxel compared to nab-paclitaxel alone. 2. The rate of adverse ...
#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Fruquintinib Plus Paclitaxel Improved Progression-Free Survival in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Paclitaxel-coated balloon may be superior to uncoated balloon for coronary in-stent restenosis
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease
1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated ...
No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease
1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated ...
#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Tislelizumab significantly improves survival outcomes in advanced or metastatic esophageal squamous cell carcinoma
Click to read this study in the Journal of Clinical Oncology.
